Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors

Inclusion Criteria14

• age ≥18 years;
• pathologically confirmed gastrointestinal tumors (including esophageal cancer, gastric cancer, colorectal cancer, etc.);
• during the previous chemotherapy cycle (N-1 cycle), patients had a minimum platelet count of ≥75×10⁹/L and at least one high-risk bleeding factor (① history of bleeding; ② previous treatment with platinum agents, gemcitabine, cytarabine, anthracyclines, etc.; ③ tumor cell bone marrow infiltration; ④ previous or ongoing radiotherapy, especially to long bones or flat bones such as the pelvis or sternum);
• during the current chemotherapy cycle (N cycle), patients have a platelet count of ≥100±25×10⁹/L;
• undergoing treatment cycles of 14 or 21 days and requiring at least one more cycle of therapy.
• ECOG score: 0-2 points;
• Adequate hematopoietic, liver, and kidney function:
• Neutrophil count ≥ 1.5 x 10⁹/L
• Hemoglobin ≥ 9.0 g/dL
• Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula)
• For patients without liver metastasis, AST and ALT ≤ 2.5 times the upper limit of normal;
• Bilirubin ≤ 2 times the upper limit of normal;
• APTT and PT ≤ 1.5 times the upper limit of normal
• Signed informed consent form.